We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Technology Tracks Hidden Cancer Cells Faster

By LabMedica International staff writers
Posted on 04 Dec 2025

Targeting and treating disease often hinges on the ability to locate specific cells inside the body—a challenge made difficult because harmful or therapeutic cells move through tissues and are not easily detected. More...

Now, a new technology designed to track these cells with single-cell precision could lead to more effective therapies.

Researchers at Case Western Reserve University (Cleveland, OH, USA) are advancing their technology that enhances the ability to locate therapeutic cells or diseased cells like cancer. Their platform, based on the CryoViz cryo-imaging system, generates high-resolution 3D images using robotics, microscopy, and advanced software. By integrating artificial intelligence (AI) and machine-learning tools, the CryoViz cryo-imaging device can automatically identify healthy and diseased tissues, detect fluorescently labeled cells, and enable “virtual staining” to examine samples at a single-cell level.

By drastically reducing the time and complexity of whole-body imaging—mapping an entire mouse in hours instead of using millions of tissue sections—the approach aims to transform how researchers track metastatic cancer cells, evaluate T-cell behavior during immunotherapy, and assess drug delivery or imaging agents. The team will also use an AI-based “virtual staining” approach to evaluate the body’s tissue at a single-cell level, allowing them to track individual cells such as migrating or metastatic cancer cells and T-cells. This capability will help assess cell-based treatments treatments like immunotherapy.

“The computer can decide when it has detected some “glowing” fluorescent cells, like metastatic tumor cells in the lung,” said CWRU researcher Susann Brady-Kalnay. “It will automatically save tissue sections in that region so I can go back and study the tissue in detail at the cellular and molecular level.”

Related Links
Case Western Reserve University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.